Prevnar market report points to faster growth in adult vaccination and emerging markets

The Business Research Company says the global Prevnar vaccine market is set for continued growth through 2035, driven by higher-valency vaccines, adult immunization efforts and wider access in emerging economies. North America led the market in 2025, while Asia-Pacific is projected to grow the fastest over the forecast period.

Why it matters: - Prevnar vaccines help prevent pneumococcal infections that can lead to pneumonia, meningitis, sepsis and ear infections. - The market matters because rising disease burden, aging populations and uneven vaccination coverage continue to support demand for pneumococcal prevention. - Growth in adult and elderly vaccination could expand the market beyond pediatric use.

What happened: - The Business Research Company published its Prevnar Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the Prevnar vaccine market grew steadily during the historical period. - The company released a free sample of the report and a full report online: Download the sample report and view the full market report. - The release was dated Nov. 9, 2026, from London.

The details: - Prevnar vaccines use conjugate technology that links polysaccharides to proteins to improve immune response. - The vaccines are designed to protect against infections caused by Streptococcus pneumoniae. - The report says infants, older adults and immunocompromised people are especially vulnerable to pneumococcal disease. - Historical growth was supported by national immunization programs, more pneumococcal disease cases, regulatory approvals for conjugate vaccines and broader pediatric coverage. - Forecast growth is expected to come from higher-valency pneumococcal vaccines, stronger adult immunization schedules, higher government procurement and greater preventive-health spending. - Expanded availability in emerging economies is also expected to support market growth. - The report flags several future trends: broader vaccination programs, newer conjugate vaccine technologies, more adult and elderly immunization, improved cold-chain distribution and wider global coverage. - Statens Serum Institut reported invasive pneumococcal disease cases rising from 553 in 2022 to 622 in 2023. - In 2025, North America was the largest Prevnar market. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The report points to a market shift from routine childhood vaccination toward broader life-stage immunization. - Higher-valency vaccines suggest manufacturers are competing on broader strain coverage, not just volume. - Better cold-chain logistics and wider access in emerging economies could matter as much as clinical demand.

What's next: - The report expects continued market expansion through 2035 as vaccine access widens and immunization programs broaden. - Government procurement and preventive-health investment are likely to remain important demand drivers. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - The company also provided contact details for further inquiries and a LinkedIn page: The Business Research Company.